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Naturally Occurring Carboxypeptidase A6 Mutations
EFFECT ON ENZYME FUNCTION AND ASSOCIATION WITH EPILEPSY *□
S
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Matthew R. Sapio‡, Annick Salzmann§, Monique Vessaz¶, Arielle Crespel储, Peter J. Lyons**, Alain Malafosse§¶,
and Lloyd D. Fricker‡ ‡‡1
From the ‡Department of Neuroscience and the ‡‡Department of Molecular Pharmacology, Albert Einstein College of Medicine,
Bronx, New York 10461, the §Department of Psychiatry, University of Geneva, 1205 Geneva, Switzerland, the ¶Department of
Genetic Medicine and Laboratory, University Hospitals of Geneva, 1205 Geneva, Switzerland, the 储Department of Neurology,
Montpellier University Hospital, France, and the **Department of Biology, Andrews University, Berrien Springs, Michigan 49104
Background: Two mutations in the carboxypeptidase A6 (CPA6) gene were previously found in epilepsy patients.
Results: Many additional CPA6 mutations were found. Some inactivated CPA6 and were more frequently found in epilepsy
patients than controls.
Conclusion: Several CPA6 mutations greatly reduce enzyme activity, but the most frequently found mutations do not.
Significance: Mutations in CPA6 are associated with rare cases of epilepsy.
Carboxypeptidase A6 (CPA6) is a member of the A/B subfamily of M14 metallocarboxypeptidases that is expressed in brain
and many other tissues during development. Recently, two
mutations in human CPA6 were associated with febrile seizures
and/or temporal lobe epilepsy. In this study we screened for
additional CPA6 mutations in patients with febrile seizures and
focal epilepsy, which encompasses the temporal lobe epilepsy
subtype. Mutations found from this analysis as well as CPA6
mutations reported in databases of single nucleotide polymorphisms were further screened by analysis of the modeled
proCPA6 protein structure and the functional role of the
mutated amino acid. The point mutations predicted to affect
activity and/or protein folding were tested by expression of the
mutant in HEK293 cells and analysis of the resulting CPA6 protein.
Common polymorphisms in CPA6 were also included in this analysis. Several mutations resulted in reduced enzyme activity or
CPA6 protein levels in the extracellular matrix. The mutants with
reduced extracellular CPA6 protein levels showed normal levels of
50-kDa proCPA6 in the cell, and this could be converted into
37-kDa CPA6 by trypsin, suggesting that protein folding was not
greatly affected by the mutations. Interestingly, three of the mutations that reduced extracellular CPA6 protein levels were found in
patients with epilepsy. Taken together, these results provide further evidence for the involvement of CPA6 mutations in human
epilepsy and reveal additional rare mutations that inactivate CPA6
and could, therefore, also be associated with epileptic phenotypes.

Epilepsy is one of the most common neurological disorders,
affecting 1–2% of the population (1) with focal epilepsy (FE)2
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accounting for ⬃60% of this prevalence (2). As proposed by the
International League Against Epilepsy, FE includes temporal,
frontal, parietal, or occipital lobe epilepsy, depending on the
localization of the seizure discharge (3). Temporal lobe epilepsy
(TLE) is the most frequent form of FE in adults, with hippocampal sclerosis being the most recurrent pathogenic feature of this
illness (4). Moreover, 25% of patients with TLE and hippocampal sclerosis often show febrile seizures (FS) during childhood
(5). Generally, FS are defined as seizures occurring during fever
episodes without any central nervous system infection (3). FS
are the most common convulsive events during early childhood
(5), being seen in 5% of the general population (6). As suggested
by segregation and linkage studies, FS (7) and TLE (8) could be
considered as complex disorders with genetic predisposition.
However, few genes have been reproducibly associated with FS
(9) and TLE (10). This may be due to the clinical heterogeneity of the patients included in almost all studies. FS and TLE
may also be caused by multiple rare and/or de novo mutations. This latter possibility is supported by the recent identification of two mutations in the carboxypeptidase A6
(CPA6) gene in a family with FS and TLE as well as in unrelated TLE patients (11).
CPA6 is an extracellular peptidase in the A/B subfamily of
the M14 family of carboxypeptidases (12). CPA6 is translated
with an N-terminal signal peptide (residues 1–30), which
routes it to the secretory pathway. Like most other members of
its subfamily, CPA6 is produced as an ⬃50-kDa inactive proenzyme, proCPA6 (residues 31– 437), that is activated when
cleaved by a furin-like enzyme into the 37-kDa form (residues
130 – 437) (13, 14). The propeptide found in most members of
the A/B carboxypeptidase subfamily acts as an intramolecular
chaperone, inhibiting enzymatic activity (15, 16). Upon secretion, CPA6 binds to the extracellular matrix (ECM), where it is
enzymatically active and cleaves bulky aliphatic and aromatic
residues from the C termini of peptides and proteins (17). CPA6
mRNA is most highly expressed in the olfactory bulb and epididymis of the adult mouse and is more broadly expressed in the
developing forebrain and cerebellum as well as in developing
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TABLE 1
Demographic and clinical characteristics of FE patients, FS patients, and Caucasian controls
HS, hippocampal sclerosis; NA, number of patients for whom no information is available
Subjects
FE patients
FS patients
Controls

n

Male

Female

%

%

Age at
Age at
inclusion ⴞS.D. onset ⴞS.D.

99 (50.8) 32.83 ⫾ 11.19
NA 3
97 51 (52.6) 46 (47.4) 9.47 ⫾ 13.21
NA 6
242 171 (70.7) 71 (29.3) 44.8 ⫾ 12.8

195 96 (49.2)

14.37 ⫾ 9.22 89 (46.8)
NA 13
NA 5
1.68 ⫾ 1.73
NA 63

skin, bone, and osteoblasts (18). CPA6 mRNA has been identified in the human central nervous system, notably the hippocampus (11).
One of the previously identified CPA6 mutations results in a
substitution at alanine 270 (A270V) and appears to be linked to
a familial autosomal recessive form of FS and TLE, whereas
the other, a missense mutation at glycine 267 (G267R), is
associated to unrelated TLE patients in the heterozygous
state (11). Biochemical analysis revealed that the A270V
mutation retains full carboxypeptidase activity but is present
in ECM at about 40% that of the wild type (WT) level in the
ECM. The G267R mutation was not detectable in the ECM.
Although CPA6 has been shown to perform biologically significant cleavages on several peptides in vitro (13, 17), the
function of CPA6 as well as the mechanism by which these
mutations may lead to epilepsy remains unknown. Because
both mutations reduce the level of CPA6 protein in the ECM,
it remains unclear whether carboxypeptidase activity or the
level of the protein is responsible for the observed effects of
these mutations.
Given what is known about the G267R and A270V mutations, we hypothesized that loss of function of CPA6 could lead
to seizures and epilepsy. Because other mutations in the CPA6
gene should be capable of reducing or eliminating the function
of the protein, we searched for and found additional CPA6
mutations in FE and FS populations. Modeling of these mutations as well as other mutations reported in databases of single
nucleotide polymorphisms (SNPs) suggested that many mutations in the CPA6 gene could alter structural integrity, carboxypeptidase activity, or both and thus could potentially be related
to the disease. We analyzed these mutant proteins using a variety of methods to better understand their relationship to seizures and epilepsy.

EXPERIMENTAL PROCEDURES
Subjects—This study was approved by the ethics committees
from the departments of neurology and pediatrics from the
University Hospitals of Geneva. The FE group consisted of
patients who suffered from non-lesional FE and lesional FE
such as vascular malformation, cortical dysplasia, and nervous
system tumor (Table 1). These unrelated Caucasian patients
showed the following distribution of epilepsy syndromes
already described in a previous paper (11): 138 patients with
TLE (70.8%), 28 patients with undetermined focal epilepsy
(15.4%), 12 patients with frontotemporal epilepsy (6.2%), 4
patients with parietal epilepsy (2.1%), 2 patients with temporoparietal junction epilepsy (1.0%), 2 patients with parietooccipiDECEMBER 14, 2012 • VOLUME 287 • NUMBER 51

HS

Personal
Familial history Simple Complex Personal history
history of FS of FS/epilepsy
FS
FS
of epilepsy
%

69 (35.6)
NA 1

%

32 (17.5)
NA 12
33 (84.6)
NA 58

%

%

NA 195 NA 195
30 (56.6) 23 (43.4)
NA 44 NA 44

16 (21.1)
NA 21

tal epilepsy (1.0%), 2 patients with temporolateral epilepsy
(1.0%), 2 patients with temporooccipital epilepsy (1.0%), 1
patient with parietotemporal epilepsy (0.5%), 1 patient with
multifocal epilepsy (0.5%), and 1 patient with Rasmussen syndrome (0.5%). These patients suffered from a severe form of
epilepsy with poor control of their seizures. Diagnosis was
based on patient history, clinical examination, interictal, and
ictal electroencephalography (EEG) analysis carried out with
monitoring video-EEG and magnetic resonance imaging
evaluation.
Unrelated Caucasian patients with FS were admitted to the
pediatric emergency rooms at the University Hospitals of
Geneva, Lausanne, and Neuchâtel (Switzerland) (Table 1). At
that time, these patients were recruited following the Consensus statement (19). Simple FS were defined when the seizures
were brief with a single seizure occurring during a febrile illness. If duration exceeded 15 min or if multiple seizures
occurred during a single febrile illness or within the first 24 h
period, they were defined as complex FS.
A healthy Caucasian control group (West European origin
for at least two generations) was recruited from blood donors at
the University Hospitals of Geneva (Table 1). Only unrelated
blood donors without a personal and/or familial history of epilepsy and seizures were included.
Mutation and Single Nucleotide Polymorphism Screening—
All patients and controls or their legal representatives gave
their informed consent, and then venous blood was collected in
EDTA tubes. DNA was extracted from peripheral blood leukocytes using the Nucleon BACC 2 kit (GE Healthcare). CPA6
exons were explored using a high resolution melt assay, which is
a rapid, highly reproducible, and resolutive process. Previous
experiments have shown a sensitivity and specificity
between 97 and 99% for PCR products up to 1000 bp (20, 21).
We used this method followed by direct sequencing to confirm mutations and SNPs as described (11). PCR and high
resolution melt assay conditions and primers sequences are
available on request. For high resolution melt data analysis,
we normalized melting curves for each sample by calculating
the “line of best fit” between two normalization regions
before and after the major fluorescence decrease representing the melting of the PCR product using the software provided by the Rotor-GeneTM 6000 (Corbett Research, Australia). This algorithm allows the direct comparison of samples
that have different starting fluorescence levels with control
samples, which were previously sequenced to determine
genotype (22).
JOURNAL OF BIOLOGICAL CHEMISTRY
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Statistical Analysis—First, we checked Hardy-Weinberg
equilibrium by using a 2 goodness-of-fit test. Then differences
in allele frequencies between cases and controls were determined using UNPHASED software (Version 3.0.10) (23). The
statistical power to detect association was estimated using the
Genetic Power Calculator. For every calculation we used a genotype relative risk for a heterozygote of 2, for a homozygote of 3,
and an additive model at ␣ level ⫽ 0.05. Therefore, we found
that for rs17343819, FE patients had 94% power to detect a risk
allele G with 13% frequency in controls and a disease prevalence
of 0.5% (1, 24). The power was 84% for FS patients with a disease
prevalence of 2% (6). For rs17853192, FE patients had 82%
power to detect no significant association with a risk allele G
with 7% frequency in controls. The power was 68% for FS
patients.
Protein Analysis and Modeling—CPA6 protein sequences
were accessed from The National Center for Biotechnology
Information. Sequence alignment was performed using ClustalW and analyzed using GeneDoc to quantify homology
between human CPA6 and orthologs in other vertebrates.
Modeling of CPA6 protein structure has been described previously (17). Mutations were modeled using Swiss PDB Viewer
and PyMOL. Images were created using PyMOL.
Site-directed Mutagenesis—Point mutations were introduced into the pcDNA3.1(⫺)hCPA6-HAH6 plasmid (13) using
PfuUltra II Hotstart DNA Polymerase (Agilent, Santa Clara,
CA) or Pfu Turbo (Stratagene, La Jolla, CA) using the
QuikChange mutagenesis protocol (Stratagene). The resulting
cDNA constructs code for full-length human preproCPA6 protein with the hemagglutinin (HA) and hexahistidine (H6)
epitopes at the C terminus (13). All mutations were confirmed
by DNA sequence analysis.
Cell Culture and Analysis of CPA6 Mutant Proteins—
HEK293T cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37 °C and 5% CO2. Cells were transfected
with human CPA6 cDNA using TransFectin (Bio-Rad) according to the manufacturer’s instructions. The amount of plasmid
used in transfection was adjusted so that expression levels of
proCPA6 in cell lysates were equal when examined by Western
blot (data not shown). At 48 h post-transfection, cells were harvested in phosphate-buffered saline (PBS) and centrifuged, and
the pellet was sonicated in PBS solution containing 0.1% Nonidet P-40. Aliquots were analyzed on a denaturing polyacrylamide gel. After harvesting cells from the culture dish, the ECM
remaining on the dish was washed several times with PBS to
remove any remaining cells. ECM samples were analyzed for
CPA6 activity by incubating for 2 h at 37 °C with 0.5 mM 3-(2furyl) acryloyl-Phe-Phe (FA-Phe-Phe; Bachem, Bubendorf,
Switzerland) in Tris buffer (pH 7.8) containing 150 mM NaCl.
Reactions were stopped by transferring the soluble substrate to
polypropylene tubes, separating it from the enzyme, which
remained bound to the ECM. Solutions were transferred to
cuvettes, and carboxypeptidase activity was detected by a
decrease in absorbance at 336 nm as described previously (13).
After incubation with FA-Phe-Phe, the same ECM samples
were collected by the addition of SDS-PAGE sample buffer,
fractionated on SDS-PAGE, and transferred to nitrocellulose.

42902 JOURNAL OF BIOLOGICAL CHEMISTRY

Western blotting was performed according to standard protocol with mouse anti-HA (clone HA-7, Sigma; 1:5000 dilution)
primary antibody and either IRdye800-congugated anti-mouse
secondary antibody (Rockland, Gilbertsville, PA; 1:3000 dilution) or horseradish peroxidase-conjugated anti-mouse secondary antibody (Cell Signaling, Danvers, MA; 1:2000). Images
were obtained and quantified using the Li-COR Odyssey System (Lincoln, NE) or with enhanced chemiluminescence detection reagent.
In experiments where levels of CPA6 protein expression
were compared between media and ECM fractions, cells were
cultured in reduced volumes of media beginning at 24 h posttransfection to ensure detection of CPA6 protein in the media
fractions. As a positive control, 400 g/ml heparin was added at
24 h post-transfection to solubilize CPA6 to show that CPA6
could be detected in the media when present. At 48 h posttransfection, media samples were collected, and cells were harvested in PBS, combined with SDS-PAGE sample buffer, and
analyzed by Western blotting, as above.
In experiments testing the thermal stability of CPA6, ECM
samples were washed to remove cells and cell fragments as
described above. Samples were incubated in PBS at the indicated temperature for 1 h. After heating, PBS was removed,
and samples were assayed for carboxypeptidase activity as
described above. In experiments to determine if oxidation
reduces the enzymatic activity of CPA6, a similar method
was employed. In place of heating for 1 h, ECM samples were
incubated with 2% hydrogen peroxide (w/w) for 30 min at
22 °C on a rotating platform (25). Samples were then washed
several times with PBS to remove remaining hydrogen peroxide before assaying for carboxypeptidase activity.
In experiments where trypsin was used to digest proCPA6,
cells were lysed as described above and incubated with trypsin
for 1 h at 37 °C at a broad range of concentrations. A 1:1 concentration of trypsin represents a stock solution of 0.2 g/l of
trypsin in trypsin resuspension buffer (Promega, Fitchburg,
WI), from which other concentrations were prepared by serial
dilution.

RESULTS
Mutations and SNPs Screening—To screen for additional
mutations in CPA6, an exonic high resolution melt analysis was
performed. A previously unpublished missense mutation
c.843A3 G was found in a heterozygote FE patient (ET 174).
This mutation changes a histidine at position 196 into an arginine (H196R) and was not found in 242 Caucasian controls. The
parents of the individual harboring this mutation were not
available. One FS patient (CF-29 – 0) was found with a putative
missense heterozygous mutation (Table 2). This non-synonymous mutation replaces a proline at position 16 with a threonine (P16T). The patient’s unaffected father (CF-29-2) was
heterozygous, whereas his affected mother (CF-29-1) did not
harbor the mutation (Table 2). The mutation was not found in
242 Caucasian controls.
The screening of CPA6 exons also revealed a published
genetic variant, rs35993949 (c.875C3 G) found in the
heterozygous condition in one FE patient (Table 2, subject ET
158). The SNP rs35993949 affects a glutamine residue, which is
VOLUME 287 • NUMBER 51 • DECEMBER 14, 2012

Carboxypeptidase A6 Mutations
TABLE 2
CPA6 mutations in FE and FS patients and their available relatives
NA, data not available.
Subject

CF-29-0

Sex
Age
Age at onset
Simple FS
Complex FS
Afebrile seizures
Familial FS Antecedent
IRM
CPA6 mutation
Alleles

Male
2 years
15 months
Yes
No
No
Mother
NA
c.302C 3 A (p.P16T) CA
Heterozygous

a
b

CF-29-1
(mother of CF-29-0)
Female
36 years
4 years
Yes
No
No
No
NA
c.302C 3 A (p.P16T) CC
Homozygous for Pro-16
allele

CF-29-2
(father of CF-29-0)

ET 158a

ET 174

Male
36 years

Male
20 years
7 years
No
Yes
No
No
No
Left temporal origin
No
Brother
Hippocampal sclerosis
c.302C 3 A (p.P16T) CA c.843A 3 G (p.H196R) AG
Heterozygous
Heterozygous

Male
49 years
5 years
No
No
Temporal origin
Paternal grandfather
Cavernous malformation
c.875C 3 G, (p.Q207E) CG
Heterozygousb

Data from this patient were published previously (11).
This patient also harbors the G267R mutation.

replaced by a glutamic acid residue (Q207E). The putative pathogenic G-allele was not found in 242 Caucasian controls. In a
previous study we reported a heterozygous missense mutation
(G267R) for patient ET 158 (11). Further analysis shows that
patient ET 158 is compound heterozygous for the two pathogenic non-synonymous mutations c.875C3 G (Q207E) and
c.799G3 A (G267R) on exons 6 and 8, respectively. As parents
of ET 158 were not available, we could not determine whether
these two mutations are de novo.
Three common allelic variations were examined. First, we
checked Hardy-Weinberg equilibrium to test if both allele
and genotype frequencies in our patient and control populations remained constant through generations (26). The
rs17853192 (C3 G 3 S173C) and rs17343819 (A3 G 3
N249S) genotypic distributions were at Hardy-Weinberg
equilibrium among FE and FS patients and controls (Table
3). The rs10957393 (T3 C 3 F45L) genotypic distributions
were at Hardy-Weinberg equilibrium among FS patients
(p ⫽ 0.39) but at the limit in FE patients (p ⫽ 0.03) and in
controls (p ⫽ 0.02).
The SNP rs17343819 showed a significant difference
between FE patients and controls (Table 3). The G-allele displayed a higher frequency in FE patients (21.0%) than in unaffected cases (13.7%). This difference reached statistical significance with a p value of 0.0041. Moreover, the AA genotype
appears to be protective against FE because controls show a
higher frequency (74.0%) than FE patients (61.0%) (p ⫽ 0.013).
No significant genotypic and allelic differences were found
between FS patients and controls. For rs17853192 and
rs10957393, no associations were found for FE or FS patients
compared with controls.
Modeling of CPA6 Mutations within Predicted Protein
Structure—In addition to the mutations described above in FE
and FS patients, a large number of additional mutations in the
CPA6 gene were reported in the National Center for Biotechnology Information SNP database (www.ncbi.nlm.nih.gov) and
in the 1000 Genomes Project. We first examined all SNP mutations and selected those that were exonic and that resulted in a
missense mutation (supplemental Table S1). These mutations
were examined for conservation from human to zebrafish (supplemental Fig. S1) and across members of the carboxypeptidase
A subfamily (supplemental Fig. S2). SNPs were selected based
on a variety of factors including frequency of the allele, conserDECEMBER 14, 2012 • VOLUME 287 • NUMBER 51

TABLE 3
Allele and genotype count in FE, FS patients, and controls
Bold indicates statistically significant p values.
Genetic variation
rs10957393 (T 3 C 3 p.F45L)
Allele
T
C
P
Genotype
TT
TC
CC
p
rs17853192 (C 3 G 3 p.S173C)
Allele
C
G
p
Genotype
CC
CG
GG
p
rs17343819 (A 3 G 3 p.N249S)
Allele
A
G
p
Genotype
AA
AG
GG
p

Controls
n

FE n

FS n

%

%

%

466
378 (81.1)
88 (18.9)
233
148 (63.5)
82 (35.2)
3 (1.3)

476
439 (92.6)
35 (7.3)
238
202 (85.2)
35 (14.8)
0 (0.0)

476
411 (86.3)
65 (13.7)
238
176 (74.0)
59 (24.8)
3 (1.2)

390
312 (80.0)
78 (20.0)
0.681
195
120 (61.5)
72 (36.9)
3 (1.5)
0.904

192
165 (85.9)
27 (14.1)
0.132
96
70 (72.9)
25 (26.0)
1 (1.1)
0.252

390
368 (94.4)
22 (5.6)
0.302
195
173 (88.7)
22 (11.2)
0 (0.0)
0.284

192
178 (91.8)
16 (8.2)
0.705
96
81 (83.5)
16 (16.5)
0 (0.0)
0.692

390
308 (79.0)
82 (21.0)
0.0041
195
119 (61.0)
70 (35.9)
6 (3.1)
0.013

192
168 (87.5)
24 (12.5)
0.689
96
72 (75.0)
24 (25.0)
0 (0.0)
0.360

vation, severity of the change in amino acid, location of the
residue, and predictions from PolyPhen and SIFT, which analyze conservation of mutated residues across species and the
predicted severity of amino acid substitutions (supplemental
Table S1). Several nonsense mutations were found in the SNP
database that produced truncations of the protein due to frameshifts and/or introduction of stop codons. All of these were
predicted to result in inactive CPA6 protein, based on the
requirement for an active site Glu residue known to be involved
with catalytic function (13). Missense mutations in CPA6 were
visualized within the structural model of the CPA6 protein, as
previously described (17) (supplemental Fig. S3). These mutations were organized into several categories based on biochemical properties, the frequency at which they occur in humans,
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 1. Mutations identified in the CPA6 protein. This study examines
the biochemical properties of twelve mutations in the CPA6 protein (sticks).
These mutations occur throughout the protein, and the residues they alter
likely have diverse effects on structure and function.

and the level of conservation of the amino acid that they alter.
The F45L, S173C, and N249S mutations, which occur frequently in humans, were predicted to be harmless or minimally
damaging to the protein. These mutations represent modest
changes in that these amino acids are not highly conserved and
the substituted amino acid was not predicted from our analysis
to alter the conformation or function of the protein (supplemental Table S1). The H196R, Q207E, R311E, and A424V
mutations were predicted to greatly diminish CPA6 activity.
The H196R mutation occurs at a residue that is crucial for the
coordination of the zinc ion in the catalytic region of the protein
and is necessary for the function of all metallocarboxypeptidases in the A/B subfamily (supplemental Fig. S2) (27). The
V306I, P342A, and L413F mutations were predicted to be possibly damaging (supplemental Table S1). These substitutions
occur at conserved amino acids but do not cause substitutions
that represent severe changes in properties of the residue.
Another mutation, P16T, occurs within the signal peptide and
was analyzed using SignalP (28); however, this substitution was
not predicted to result in a change in signal peptide cleavage
(supplemental Fig. S4). Mutations that were selected for further
analysis were visualized within the CPA6 protein structure (Fig.
1). Mutations were subjected to additional analysis to predict
whether any would alter mRNA splicing using Human Splicing
Finder (29). One SNP, rs17343819 (N249S), occurs within an
exon splice enhancer motif in exon 7, a predicted recognition
site for 9G8. This SNP results in a modest decrease in the value
assigned by Human Splicing Finder for this motif (supplemental Table 2).
Biochemical Analysis of CPA6 Mutants—Twelve of the naturally occurring mutations were selected for direct testing of
the biochemical properties. Two of these, G267R and A270V,
were mutations we had previously tested for enzyme activity
(11); these were further characterized in the present study.
Although not identified in humans, the active site mutation
E398Q, which has no detectable carboxypeptidase activity (13),
was included as a negative control.

42904 JOURNAL OF BIOLOGICAL CHEMISTRY

Mutants were expressed in HEK293 cells, and ECM samples
were assayed for carboxypeptidase activity (Fig. 2). The F45L
mutation was the only mutation that showed no statistically
significant difference in activity from WT. The N249S mutation retained 89% of WT activity. Surprisingly, the S173C mutation showed only approximately half of the WT activity. The
H196R and A424V mutations had no detectable activity,
whereas the Q207E mutant had 11% of WT activity. We estimate that we would be able to detect activity comparable to 5%
of WT activity by our assay, indicating that these mutations
remove ⬎95% of carboxypeptidase activity. The G267R and
E398Q mutations also resulted in a similar near total reduction
in carboxypeptidase activity, as previously reported (11). The
remaining mutations resulted in an intermediate level of
retained carboxypeptidase activity. When we examined expression levels of CPA6 protein in the ECM, we found that many of
the mutants that showed a reduction in carboxypeptidase activity were expressed at reduced levels in the ECM. For the A270V
and V306I mutants, reduced expression likely accounts for the
observed reduction in activity. Although it cannot be ruled out,
this is unlikely for the N249S mutant, which shows a measurable reduction in activity but not in expression levels in the ECM.
Notably, some mutations such as the A424V had no detectable
carboxypeptidase activity but an intermediate level of protein
expression in the ECM. Conversely, the S173C and V306I
mutations showed a vast reduction in ECM expression and an
intermediate reduction in carboxypeptidase activity. No CPA6
protein was detectable in the media for WT or any of the
mutant proteins (Fig. 2B), and when heparin was added to displace protein from the ECM into the media, mutant protein
expression in the media was detected in approximately the
same ratio as it was in the ECM (Fig. 2, B–E).
From the comparison of activity versus protein levels, it
appeared that the S173C mutant had more activity than
expected based on the amount of CPA6 protein, relative to WT
CPA6 (Fig. 2, A and C). A potential explanation is that the WT
CPA6 in the ECM was not fully active, whereas a greater proportion of the S173C mutant had full activity. One mechanism
by which WT CPA6 activity could be reduced without a corresponding decrease in protein would be through oxidization of
the methionine residue present in a key position within the
substrate binding pocket. In all species examined, CPA6 contains a methionine in the position that confers specificity
toward hydrophobic amino acids (supplemental Figs. S1 and
S2); in other related enzymes (carboxypeptidases A1, A2, A3,
A4, and A5) the comparable residue is a leucine, isoleucine, or
valine and never a methionine. Methionine can become oxidized into the sulfoxide and sulfone, and this change is predicted to eliminate the ability of CPA6 to bind peptides with
hydrophobic C termini. Therefore, we tested whether oxidation reduced CPA6 activity. Treatment of WT CPA6 with
hydrogen peroxide lowered the amount of enzyme activity by
about 60% (Fig. 3). S173C, which has an outward-facing cysteine residue, did not show a significant reduction in activity
after exposure to the oxidizing chemical. As a control, the
N249S mutation was also examined. This mutant showed a
similar reduction in activity as WT CPA6 upon exposure to
hydrogen peroxide. To test the possibility that CPA6 could
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FIGURE 3. Effects of hydrogen peroxide treatment on CPA6 activity.
HEK293T cells were transfected with WT or S173C or N249S CPA6 constructs.
ECM-bound CPA6 was incubated with or without 2% hydrogen peroxide for
30 min at 22 °C and assayed for activity using the chromogenic carboxypeptidase substrate FA-Phe-Phe. After treatment with hydrogen peroxide, WT
activity was reduced by ⬃40% (n ⫽ 4, p ⬍ 0.001), whereas S173C showed only
a modest reduction that was not statistically significant (n ⫽ 5, p ⬎ 0.2). The
N249S mutation was reduced by ⬃30% (n ⫽ 5, p ⬍ 0.01).

FIGURE 2. Activity and expression level of CPA6 mutants. WT CPA6 and
CPA6 mutants were expressed in HEK293T cells and tested for activity and
extracellular expression levels. Mock transfected cells (⫺) and cells transfected with an active site mutant, E398Q, were included as negative controls.
All CPA6 constructs contained an HA tag on the C terminus for protein detection. A, the ECM-bound CPA6 was assayed for enzyme activity using the chromogenic carboxypeptidase substrate FA-Phe-Phe. B and C, the ECM samples
were resolved by SDS-PAGE, and Western blots were performed using an
antibody against the HA epitope to determine the relative level of CPA6 protein bound to the ECM. A number of mutants showed a reduction in the
amount of protein bound to the ECM (quantified in panel C). D and E, media
were analyzed on Western blots. In the absence of heparin, CPA6 protein was
undetectable in media. With the addition of 400 g/ml heparin, which displaces CPA6 from the ECM, CPA6 was detectable in the media in approximately the same ratio as in the ECM (quantified in panel E). Error bars indicate
S.E. (n ⫽ 3–25). Rare mutations found in patients with epilepsy are indicated
in bold. ND, not detected; ns, not statistically significant.
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have altered enzymatic activity when the methionine was converted into the sulfoxide or the sulfone, the hydrogen peroxidetreated CPA6 was tested with residues representing bulky
hydrophobic residues, small hydrophobic residues, and basic
residues. However, no change in substrate specificity was
observed between treated and untreated CPA6 (supplemental
Fig. S5).
The A270V mutation was analyzed for heat stability because
of its connection to febrile seizures and to examine possible
reasons for its reduced expression in the ECM. A change in heat
stability indicates a difference in folding, which could serve as
an explanation for the pathological properties of the A270V
mutation. This assay has been used to characterize mutants of
other carboxypeptidases (30). A modest reduction of carboxypeptidase activity was detected at 48 °C, and the A270V mutant
showed a greater reduction than the WT form (Fig. 4A). At
temperatures above 48 °C, both WT and A270V enzyme activity were greatly reduced and were not significantly different
between WT and A270V. Other mutants with detectable activity were tested after a 48 °C heat treatment; however, none
showed a significant difference when compared with WT CPA6
(Fig. 4B), indicating that the A270V may be unique in this property among the mutants tested.
Because proteins that are misfolded are often degraded
before secretion, we tested if CPA6 mutants that have no
detectable expression in the ECM are more sensitive to trypsin
digestion, which could indicate a change in folding pattern and
domain structure. All of the mutant proteins tested showed the
same bands representing the 50-kDa proCPA6, the ⬃37-kDa
active CPA6, and a ⬃25-kDa degradation product that likely
corresponds to a cleavage at a region rich in basic amino acids
(residues 178 –187) (Fig. 5, supplemental Fig. S6). Grossly misfolded proteins often show smears due to the accessibility of
trypsin to many basic residues, whereas correctly folded proteins will be preferentially cleaved by trypsin at a limited number of basic residues that are accessible to the enzyme. The
similar sizes of the trypsin digestion products indicates that the
mutant proteins form stable structures that resemble the WT
form of CPA6.
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FIGURE 4. Heat stability of CPA6 mutants. HEK293T cells were transfected with WT and mutant CPA6. ECM-bound CPA6 was incubated at the temperature
indicated for 1 h and then transferred to 37 °C and assayed for CPA6 activity using the chromogenic carboxypeptidase substrate, FA-Phe-Phe. A, the A270V
CPA6 mutant showed slightly decreased activity when incubated at 48 °C (WT, n ⫽ 12; A270V, n ⫽ 6; p ⬍ 0.05). Other temperatures showed a tendency toward
reduced activity, but this was not significant. B, other CPA6 mutants with activity were tested by incubating at 48 °C for 1 h and then cooling to 37 °C for enzyme
assay. No statistically significant differences were observed between these mutants and WT CPA6. Error bars represent S.E. (n ⫽ 5). RT, room temperature.

DISCUSSION

FIGURE 5. Digestion of proCPA6 with trypsin. HEK293T cells were transfected with WT or mutant CPA6. Cells were harvested in PBS, lysed in PBS with
0.1% Nonidet P-40, and sonicated. Samples were then centrifuged, and
supernatants were divided into aliquots and incubated for 1 h at 37 °C with
varying concentrations of trypsin as indicated. A 1:1 concentration of trypsin
represents a stock solution of 0.2 g/l trypsin, from which other concentrations were prepared by serial dilution. Both WT CPA6 and mutants, which
displayed no detectable CPA6 expression in the ECM, show distinct bands
corresponding to 50, 37, and 25 kDa, representing proCPA6, CPA6, and a
cleavage product, respectively. The E398Q mutation was included as a
control.

To test the possibility of a dominant negative action for
CPA6 mutants found in the heterozygous condition, co-expression of WT and mutant CPA6 was performed. For this, WT
CPA6 was tagged with the FLAG epitope tag, and mutants were
tagged with the HA-His6 tag. Combinations of the plasmid
encoding WT CPA6 with plasmids encoding each of the
mutants were transfected into HEK293T and the ECM assayed
for enzyme activity (supplemental Fig. S7). The combination of
WT and mutant either led to greater activity than WT alone
(for those mutants with activity) or no difference with WT
alone (for those mutants with no activity). None of the combinations showed activity lower than that of WT alone, indicating
that the mutants were not able to act in a dominant negative
fashion.
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Previously, two CPA6 mutations were identified that affected
enzymatic activity and protein levels; one mutation was linked
to familial FS and TLE, and the other mutation was associated
with sporadic TLE (11). A major finding of the present study is
that a number of additional mutations within CPA6 similarly
affect the protein and are found in patients with epilepsy.
Because both of the previously identified mutations were
located in the same substrate binding loop of the CPA6 protein,
it was unclear if the mutations acted in a related and specific
way or if other mutations affecting different parts of the protein
could also be associated with epilepsy. The new mutations identified in the present study extend the previous results and suggest that loss-of-function mutations in CPA6 are related to epilepsy and seizures. Our finding that the A270V mutation and
hydrogen peroxide treatment, each manipulations that affect
the region of the protein involved in substrate binding, had no
effect on the substrate specificity of the enzyme suggests that it
is unlikely that other mutations that occur far from the substrate binding loop affect specificity of CPA6. However,
because all of the other mutants were examined using only one
substrate, it remains a possibility that some mutations in CPA6
alter the selectivity of the enzyme. Both gain-of-function (31,
32) and loss-of-function (33–35) mutations of other genes have
been found to cause epilepsy. We expect that both types of
mutations in CPA6 could lead to epilepsy; however, in vitro
experiments present difficulties in discriminating between the
two, as it is not always clear how these mutations will affect the
human brain in vivo (36).
Generally, common variations in the CPA6 gene were not
found to markedly reduce the activity or expression of the
enzyme and were not found to be associated with epilepsy.
However, our finding that the SNP rs17343819 (A3 G 3
N249S) shows a small but statistically significant decrease in
enzyme activity and is more common in FE patients than in
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controls is consistent with the “common disease-common variant” hypothesis. Previous studies that identified susceptibility
markers for complex epilepsy predicted considerable underlying polygenic heterogeneity (37). It is possible that the modest
reduction in carboxypeptidase activity of the N249S variant
contributes to seizures. The cause of the reduction in enzyme
activity of this mutant is not known, and although ECM levels of
mutant CPA6 protein were comparable to WT CPA6 protein,
we cannot rule out a small decrease in expression of the N249S
mutant. Alternatively, this mutation may cause changes in protein function or expression that were not detected in the present study. For example, Asn-249 is the last residue coded by
exon 7 and the adenine to guanine substitution could affect
splicing because it occurs within an exon splice enhancer, offering a potential alternative explanation for the consequences of
this mutation. Although the reduction in the score assigned by
Human Splicing Finder is modest (supplemental Table S2), this
is consistent with a subtle effect of this SNP. Such results have
already been found in some epileptic contexts. The well-studied
SNP rs3812718 (IV5N⫹5 G3 A), which modifies the proportion of two SCN1A alternative transcripts, is a susceptibility
common variant for epilepsy. This SNP has been associated
with FS and FE with history of FS (38, 39). Moreover, rare nonsynonymous mutations in SCN1A have been linked to severe
myoclonic epilepsy in infancy (40). Collectively, these data
demonstrate that common variants and rare mutations of the
same gene are implicated in related epileptic syndromes. This is
consistent with the findings of the present study, as rare missense mutations and one common marker, rs17343819
(N249S), are detected in FE patients.
Several rare mutations were identified in patients with epilepsy that greatly reduce CPA6 activity and expression. The
missense mutation (G267R) was previously found in three TLE
patients (11). In the present study we found that one of these
three patients also showed another missense mutation, Q207E.
We could not confirm if these pathogenic variants were de novo
because the parents of the individual harboring these mutations
were not available. We were also unable to determine whether
or not the two mutant alleles were located on the same parental
chromosome. Because of this uncertainty, this patient is considered to be compound heterozygous for G267R and Q207E
(11). Because each of these mutations alone causes a ⬎95%
reduction in CPA6 protein levels in the ECM, it is likely that a
compound heterozygote for these mutations would show a
complete loss of functional protein. Analogous events have
been described in patients with missense mutations in POLG,
the gene encoding mitochondrial DNA polymerase ␥ (41).
Patients with these mutations display ataxia syndrome, which is
a progressive neurological disorder characterized by FE as a
primary feature (41). Some compound heterozygotes have been
reported among these patients, who harbor both A467T and
T748S mutations in POLG (42, 43). One patient, heterozygote
for T748S only, also showed a similar neurological phenotype
with epilepsy (42).
Except for the N249S polymorphism discussed above, all
other CPA6 polymorphisms that occur frequently in the population did not show any association with epilepsy. Our finding
that the SNP rs10957393 (T3 C 3 F45L) is not significantly
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associated with FE and FS groups is consistent with the observation that the F45L mutation showed normal levels of enzyme
activity when expressed in cells. The S173C mutation is another
relatively common variant in the general population. Although
the S173C mutation significantly reduced CPA6 protein levels
in the ECM, it had no apparent association with epilepsy. Notably, the S173C mutation has never been reported in the
homozygous state, and it is possible that like the A270V mutation, which also causes a partial reduction in ECM expression of
CPA6, the S173C mutation may be found to be associated with
epilepsy only when both alleles are mutated (11).
Although most of the mutants tested in the present study
showed a reduction in enzyme activity relative to the amount of
protein present in the ECM, the S173C enzyme appears to be
more active than WT CPA6 when enzyme activity is adjusted
for protein level. It is possible that CPA6 exists in a variety of
states, some more active than others. We hypothesized that
CPA6 may be regulated by oxidation and that some percentage
of CPA6 in the ECM may be oxidized at a given time. This
prediction comes from the observation that CPA6 has a methionine residue at the position that confers substrate specificity;
this methionine is conserved throughout evolution for all species where a clear CPA6 orthologue has been identified. Methionine is not present in the comparable position in any other
member of the M14 metallocarboxypeptidase family. Because
methionine is less hydrophobic when oxidized to either the
sulfoxide or sulfone, this oxidation was predicted to reduce the
ability of CPA6 to cleave peptides with hydrophobic C termini.
This prediction was confirmed; CPA6 activity is diminished
when treated with hydrogen peroxide, a standard technique to
oxidize methionines in proteins. In contrast, the S173C mutant
is resistant to hydrogen peroxide and does not lose enzyme
activity, possibly because the free Cys residue is oxidized preferentially, protecting the critical methionine from oxidation. If
the WT CPA6 in the ECM represents a mixture of protein with
reduced and oxidized methionine residues, whereas the S173C
is primarily the reduced form, this could account for the observation that the mutant has more activity than expected due to
the low level of protein.
Several of the mutations in CPA6 were predicted to affect
protein folding based on the steric hindrance imposed by the
mutation or the loss of a salt bridge. Consistent with this prediction, we found a number of the mutations had no enzymatic
activity and were not secreted from cells. Misfolded proteins
are often degraded before being routed to the trans Golgi complex for secretion, potentially providing an explanation for the
lack of secretion of some CPA6 mutants. However, all of the
mutants presumably have the same general domain structures
as they are all cleaved at the same basic regions by trypsin.
Furthermore, except for the A270V mutation, none of the
mutants showed greater thermo-instability, further supporting
similar folding patterns to WT CPA6. Although the A270V
mutant showed a significant decrease after being heated to
48 °C, indicating it may be less stable than the WT variant, this
temperature is not physiological even during extreme fever.
Similar results were found for a naturally occurring mutation of
carboxypeptidase E, with greater sensitivity to elevated temperJOURNAL OF BIOLOGICAL CHEMISTRY
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atures presumably reflecting decreased stability of the mutant
(30).
The mechanism by which CPA6 affects predisposition to seizures is not known. CPA6 is an extracellular protease that
cleaves C-terminal amino acids with a preference for large aromatic and aliphatic residues (17). When tested in in vitro assays,
CPA6 cleaves neurotensin, Met-enkephalin, and Leu-enkephalin into inactive products but converts inactive angiotensin I
into angiotensin II, the biologically active form. Many other
peptides are cleaved by CPA6; the effect on biological activity is
not currently known (13). The working hypothesis is that CPA6
plays a role in the activation of peptides that have neuroprotective effects or in the inactivation of peptides that cause neuronal
stimulation and that the reduction of CPA6 activity leads to an
imbalance of excitation and inhibition. Alternatively, it is possible that substrates or products of CPA6 play a role in development such that the reduction of CPA6 activity leads to a
nervous system that is more prone to seizures. Previously,
CPA6 deficiency was found in one patient with Duane Syndrome, an eye movement disorder caused by the failure of cranial nerve VI to innervate the lateral rectus muscle (44). Interestingly, CPA6 is expressed in the region posterior to the
developing eye. However, reduction of cpa6 levels in zebrafish
embryos had no effect on eye tracking or cranial nerve pathfinding (45). Furthermore, there are no reports of eye movement disorders in the FS or FE patients found to have point
mutations within CPA6. Thus, the link between CPA6 and
Duane Syndrome is based on a single patient, in contrast to the
link between CPA6 and epilepsy, which has now been extended
to several mutations.
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